Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (second of three parts).
D000755:Anemia, Sickle Cell / Q000097:blood / Q000628:therapy*; D000818:Animals; D003485:Cyanates / Q000009:adverse effects; D004341:Drug Evaluation; D004910:Erythrocyte Membrane / Q000378:metabolism; D004912:Erythrocytes / Q000378:metabolism; D004913:Erythrocytes, Abnormal / Q000378:metabolism / Q000502:physiology; D005782:Gels; D006451:Hemoglobin, Sickle; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008722:Methods; D010100:Oxygen / Q000097:blood; D012212:Rheology; D012995:Solubility; D014508:Urea / Q000009:adverse effects / Q000627:therapeutic use
D003485:Cyanates; D005782:Gels; D006451:Hemoglobin, Sickle; D006454:Hemoglobins; D014508:Urea; D010100:Oxygen